Skip to main content
. Author manuscript; available in PMC: 2020 May 16.
Published in final edited form as: Vaccine. 2019 Apr 19;37(22):2915–2924. doi: 10.1016/j.vaccine.2019.04.043

Figure 4. TVGV-1 vaccination increases overall survival in mice vaccinated therapeutically at day 3, 5, or 7 with TVGV-1-C, TVGV-1-G vaccines in the C3.43 HPV16-induced mouse tumor model.

Figure 4.

Mice (10/group) were vaccinated at the indicated days post tumor challenge as described in Figure 3 and followed for up to 100 days. Mice euthanized per protocol were marked as dead the following day. Significance was calculated using the log rank (Mantel-Cox) test for survival. Overall P-values (all significant) are indicated in each graph. Differences in survival between TVGV-1-C and TVGV-1-G vaccinated groups were non-significant for all therapy cohorts.